Nerlynx (neratinib) vs Orserdu (elacestrant)

Nerlynx (neratinib) is an oral tyrosine kinase inhibitor specifically approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Orserdu (elacestrant) is an oral selective estrogen receptor degrader (SERD), which is used for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer in postmenopausal women or in men with disease progression following endocrine therapy. When deciding between these two medications, it is crucial to consider the specific breast cancer subtype, previous treatments, and the molecular targets of the drugs, as Nerlynx targets HER2-positive cancers, while Orserdu is used for ER-positive, HER2-negative cancers.

Difference between Nerlynx and Orserdu

Metric	Nerlynx (neratinib)	Orserdu (elacestrant)
Generic name	neratinib	elacestrant
Indications	Extended adjuvant treatment of HER2-positive early stage breast cancer	Advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation
Mechanism of action	Tyrosine kinase inhibitor	Estrogen receptor antagonist/degrader
Brand names	Nerlynx	Orserdu
Administrative route	Oral	Oral
Side effects	Diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT elevation, nail disorders, dry skin, abdominal distention, weight loss, urinary tract infection	Not fully established as it is a newer medication but may include nausea, vomiting, fatigue, decreased appetite, and musculoskeletal pain
Contraindications	Severe liver impairment	Not fully established as it is a newer medication
Drug class	Tyrosine kinase inhibitor	Selective estrogen receptor degrader (SERD)
Manufacturer	Puma Biotechnology	Radiant Pharmaceuticals

Efficacy

Nerlynx (neratinib) Efficacy in Breast Cancer

Nerlynx (neratinib) is an oral medication that is a tyrosine kinase inhibitor specifically designed to block certain enzymes that promote cell growth in cancer cells. It is primarily used in the treatment of early-stage breast cancer and has been shown to be particularly effective in patients who have tumors that overexpress the HER2 protein. Clinical trials have demonstrated that neratinib, when used after standard adjuvant therapy with trastuzumab (another HER2-targeted therapy), can reduce the risk of breast cancer recurrence. The ExteNET study, a pivotal phase III clinical trial, showed that extending treatment with neratinib after trastuzumab therapy led to improved invasive disease-free survival compared to placebo in patients with HER2-positive early-stage breast cancer.

Orserdu (elacestrant) Efficacy in Breast Cancer

Orserdu (elacestrant) is a selective estrogen receptor degrader (SERD) that is used for the treatment of certain types of breast cancer. It is specifically indicated for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer with a certain type of genetic mutation (ESR1 mutation) who have received prior endocrine therapy. Orserdu has shown efficacy in clinical trials by improving progression-free survival in patients with these specific types of breast cancer. The EMERALD Phase 3 trial demonstrated that elacestrant significantly reduced the risk of disease progression or death compared to standard endocrine therapies in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Both Nerlynx and Orserdu are examples of targeted therapies that have expanded the options available to patients with breast cancer. Their efficacy highlights the importance of understanding the molecular and genetic characteristics of a patient's tumor to tailor treatment accordingly. As research continues, these medications may be used in various combinations or sequences to optimize outcomes for patients with breast cancer.

It is important for patients to discuss the potential benefits and risks of these medications with their healthcare providers. The efficacy of Nerlynx and Orserdu in breast cancer treatment underscores the advancements in personalized medicine and the ongoing commitment to improving survival outcomes and quality of life for patients battling this disease.

Regulatory Agency Approvals

Nerlynx

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Orserdu

Food and Drug Administration (FDA), USA

Access Nerlynx or Orserdu today

If Nerlynx or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Nerlynx

Buy Orserdu

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: